You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


FDA to review AVEO cancer drug

AVEO Oncology, a Cambridge-based cancer therapeutics company, and its Japanese partner, Astellas Pharma Inc., said Wednesday that federal regulators have agreed to review their drug candidate for kidney cancer.

In a press release, the companies said the Food and Drug Administration has accepted their new drug application for tivozanib, a treatment for patients with advanced renal cell carcinoma, or kidney cancer. Tivozanib is an investigational medicine and is not currently approved in any country. If it gets regulatory approval, AVEO said the proposed brand name for the drug is Tivopath.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week